M Lucena

Biography

M. Isabel Lucena is full Professor of Pharmacology at the University of Malaga, Head of the Clinical Pharmacology Service at the University Hospital of Malaga and Scientific coordinator of SCReN, Platform of Clinical research and clinical trials at IBIMA (2013-). Since 2022 this Clinical Trial Unit is the National Hub of ECRIN (the European Clinical Research Infrastructure Network) in Spain and hosts the European correspondent, which foster coordination of multinational clinical research. Former Vice-director (2010-2013) and Scientific Director of IBIMA (Malaga Health Research Institute) (2013-2017). Director of the Pharmacology&Paediatrics Department (School of Medicine, University of Malaga (2014-2018). President of the Accreditation Commission B8. Health Specialities, of the ACADEMIA programme (2021-2023). Belongs to CIBERehd, the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP) and leads the PAIDI CTS-649 group. Co-IP of IBIMA Group on Hepatogastroenterology, Pharmacology and Translational Clinical Pharmacology. Expert of the AEMPS (collaboration agreement 1999-) and the European Medicines Agency on liver safety. Chair of the Medical and Clinical Pharmacology Committee-of the International Union of Basic and Clinical Pharmacology (IUPHAR). Rapporteur of CIOMS working Group on Drug-Induced Liver Injury (DILI 2017-2020). Member of the Reviewing board (2016-2021) and Co-director of the Post-Graduate Course on Lifestyle and Liver Diseases for the European Association for the Study of the Liver (EASL International Liver Congress (2021).
She serves as projects' evaluator of national & international agencies and Invited speaker in international meetings. Founder and coordinator of the Spanish DILI Registry (2011) (www.spanishdili.uma.es), the Spanish Latin-American DILI Network (2011); the Prospective European DILI Registry awarded by EASL(2014). Scientific coordinator of the Cost Action 17112 Pro Euro DILI NET and of the EASL DHILI Consortium (Consortium for the study of Drug and Herbal & Dietary Supllement-Induced Liver Injury) (2022) (https://easldhiliconsortium.eu/).
The main lines of research are epidemiological studies in DILI, stratification of risk, approaches to causality assessment, and mechanistics studies: genetics and immunophenotyping studies, other omics and clinical trials design in order to improve the mechanistic understanding of DILI and the development of novel biomarkers and their transfer into clinical practice.
Participates and coordinates several international initiatives: Scientific Coordinator of the COST Action CA-7112 Pro Euro DILI NET (Prospective European Drug-Induced Liver Injury Network) (2018-2023). International collaborations: partners in the IMI Safer and Faster Evidence Based Translation consortium (SAFE-T, 2008-2015), the International Serious Adverse Event Consortium (iSAEC), IMI2 TRANSBIOLINE project (2019-2025), Eurostars Programme: Novel Combo Assay for Early Detection of DILI (E!114589-LiverAce. 2021-2023) and HALT-RONIN-Discovering chronic inflammation biomarkers that define key stages in the Healthy-to-NASH (non-alcoholic steatohepatitis) transition to inform early prevention and treatment strategies.PI WP5 HORIZON-HLTH-2022-STAYHLTH-02 (2022-2026); FDA project: Identify genetic and nongenetic factors associated with increased susceptibility to herbal dietary supplement (HDS)-induced liver injury in women.
Collaborations: Prof Kaplowitz (Universidad del Sur de California), Suzuki A. (Universidad de Duke), Aithal GP (Universidad de Nottingham), Prof E Bjornsson (Universidad de Islandia) y M Chen (National Center for Toxicological Research-FDA). This work has allowed a leading position in international DILI research.
She has received continuous competitive funding. She published over 20 book chapters and more than 250 articles in peer-review journals. She has an H-index of 55 and 11261 citations. 9th among the world experts in 'Chemical and Drug-lnduced Liver lnjury'(expertscape.com). The Instituto de Salud Carlos III leads the ranking in the area of Liver Toxicity worldwide. Position 234 in the ranking of Spanish and foreign female researchers in Spain (webometrics.info/en/investigadoras). She has directed 26 PhD thesis included 3 International thesis, 5 Extraordinary awards and 1 doctoral thesis co-tutelle with the University of Maastricht (2021). Human resources obtained through competitive convocatories: 3 technicians Garantia Juvenil (2016-2022), 3 Rio Hortega contracts (2017,2019,2023), 1 Sara Borrell (2021), 3 contracts for the Platform of Clinical research and clinical trials, 1 industrial i-PFIS IFI18/00047, 1 Phd Contract (2022) (POSTDOC_21_00780) , 1 Juan Rodés Contract JR21/00066 (2021), 1 CIBERehd Jaume Bosh Contract (2022), 1 Investigo Programme Contract (2023). Predoctoral PREP2022-000511 (MINECO 2024). 1 postdoc con el Proyecto CERTERA (CERT22/00034).